Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The Phase 2 and Phase 3 trials so far have shown a safety profile broadly consistent with other GLP-1 medications: gastrointestinal side effects are common, and a new signal called dysaesthesia (an abnormal skin sensation) appears more often at higher doses
A: Observational research suggests that people taking GLP-1 receptor agonists may have a lower risk of developing substance use disorders, but clinical trials are needed to confirm whether these drugs directly influence addiction
A flexible lazy keto or moderate lowcarbohydrate approach may therefore work well for some patients
Key Takeaway: Used off-label primarily for patients who plateau on GLP-1 alone Are Mood Effects Something to Watch For
For example, one Evernorth update (Jan 2025) designated Wegovy as a preferred generic semaglutide product under Optum Rx (for UHC plans) ( [47] ), indicating PBMs may steer covered patients toward the same products at negotiated prices
Additional caution or monitoring may be appropriate in research settings involving: Active cancer- or tumor-related research models, where antioxidant-related pathways may influence cellular-response or treatment-response mechanisms Severe asthma or hypersensitivity-prone research models, as rare sensitivity-related observations have been reported in some experimental contexts Sulfur-sensitive research models, due to Glutathione containing a thiol (sulfur-containing) group Complex hepatic-function or detoxification-related investigations, where antioxidant modulation may influence oxidative-stress or liver-related biomarkers Research conditions, research amounts, protocol duration, administration frequency, and concurrent compounds may influence tolerability observations across experimental settings
US$ 23.10
US$ 20.83
US$ 28.18
US$ 23.79
US$ 24.53
US$ 28.82
US$ 28.09
US$ 21.72
US$ 23.56
US$ 28.59
